Interactive Financial View

Financial
Dashboard

This dashboard is designed for fast investor-facing reading rather than operational overload. It uses the same canonical finance model as the Turkish version, but presents the essentials in natural English.

€14.8M2031 revenue target
€7.92M2031 net profit
2030cumulative break-even
€1.64Mbase-model capex
Reading Guide

What this dashboard is trying to show

The point is not just that the business becomes profitable. The point is how profitability is constructed: through phased capex, verified quality, a diversified product mix and disciplined market sequencing.

The base model includes only 2026-2027 establishment capex. Later phases remain roadmap expansion items.
Break-even should be read cumulatively, not only on an annual profit basis.
Essential oils and standardized extracts drive the 2031 revenue structure; hydrosols remain a supporting layer.

Scenario-Based Profitability

The same core model can be read through three different lenses: optimistic, fair and stress. The fair case remains the default decision framework.

Income Statement View

Line Item 2026 2027 2028 2029 2030 2031
This table uses the canonical approved model and stays aligned with the English strategy page.

2031 Revenue Mix

Capital Roadmap

2026

Central facility setup

Facility shell, production infrastructure, lab readiness and site activation.

€585K
2027

Analytical and extraction backbone

Extraction capability, analytical equipment, storage and export-grade readiness.

€1.06M
Roadmap

Expansion phases

Capacity upgrade and activated carbon remain roadmap capex, not embedded base-case assumptions.

€2.40M

Funding Logic

€350KIPARD grant ceiling per application
4 PhasesPhased scale-up plan with controlled capital deployment
EU FirstMarket validation sequence before broader premium expansion
The capital story is intentionally conservative. The model protects itself from overstating profitability by separating base-case capex from roadmap expansion capex.

Cash Flow Interpretation

2026-27

Investment period

Revenue is effectively absent while setup and establishment capex dominate the profile.

Negative
2028

First commercial year

The business enters revenue generation, but cumulative cash remains heavily negative.

€535K
2029

Scale-up year

Annual profitability turns strong, but cumulative cash remains below zero at year-end.

+€1.20M
2030+

Break-even and maturity

The cumulative curve turns positive in 2030, with 2031 reflecting the mature base-case profile.

Positive